Improved prefrontal activity in AD/HD children treated with atomoxetine: a NIRS study

Area of Science:

• Neuroscience
• Pediatric Psychiatry
• Medical Imaging

Background:

• Attention deficit/hyperactivity disorder (AD/HD) is a common neurodevelopmental disorder.
• Atomoxetine (ATX) is a non-stimulant medication approved for AD/HD treatment.
• Understanding ATX's effects on brain activity is crucial for optimizing treatment.

Purpose of the Study:

• To investigate the impact of long-term atomoxetine (ATX) treatment on prefrontal hemodynamic activity in children with AD/HD.
• To evaluate the utility of near-infrared spectroscopy (NIRS) in assessing treatment response.

Main Methods:

• Prefrontal hemodynamic activity was measured using NIRS in 12 children with AD/HD before and after ATX treatment (≥6 months).
• A continuous performance task (CPT) was used to elicit cognitive-related hemodynamic responses.
• Fourteen typically developing children served as a control group.

Main Results:

• Typically developing children showed increased oxygenated hemoglobin (oxy-Hb) in the dorsolateral prefrontal cortex (DLPFC) during CPT.
• AD/HD children pre-ATX showed no significant oxy-Hb increase and a decrease in the left ventrolateral prefrontal cortex (VLPFC).
• Post-ATX, AD/HD children exhibited right DLPFC activation and normalized left VLPFC response during CPT.

Conclusions:

• Long-term atomoxetine treatment positively modulates prefrontal hemodynamic activity in children with AD/HD.
• NIRS is a valuable tool for assessing prefrontal hemodynamic responses to ATX therapy in AD/HD.
• Findings support ATX as an effective treatment for improving cognitive-related brain function in pediatric AD/HD.